Clinical significance of serum interleukin-6 and −174 G/C promoter polymorphism in Rheumatoid arthritis patients

Gaber, Wafaa; Azkalany, Ghada S.; Gheita, Tamer A.; Mohey, Abeer; Sabry, Randa

doi:10.1016/j.ejr.2012.11.002

Cited by 41 publications

(18 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our results are in line with recent reports showing the higher IL‐6 concentration in Egyptian (mainly CC homozygous) patients with RA than in healthy subjects, and increased IL‐6 serum levels among European patients with the C allele …”

Section: Characteristics Of Ra Patientsmentioning

confidence: 87%

“…A positive correlation between IL‐6 concentration in patients and disease activity was also previously reported by van Leeuven et al, while Gaber et al observed a negative correlation of this cytokine level with DAS28 in heterozygous patients. However, we did not observe any direct association between IL‐6 serum levels and DAS28 in our cohort of RA patients.…”

Section: Characteristics Of Ra Patientsmentioning

confidence: 99%

See 1 more Smart Citation

Interleukin 6 gene polymorphism is associated with protein serum level and disease activity in Polish patients with rheumatoid arthritis

Wielińska

Dratwa

Świerkot

et al. 2018

HLA

View full text Add to dashboard Cite

IL-6 is a pro-inflammatory cytokine involved in development of rheumatoid arthritis (RA). The present study aimed to determine the possible association of the IL6 (rs1800795, G>C) polymorphism with RA susceptibility, disease progression and protein serum levels. Distribution of IL6 alleles and genotypes was similar in RA patients and controls. As expected, patients before induction of anti-TNF agents had significantly higher IL-6 levels as compared to controls (p=0.002). The CC homozygous patients were characterized with the highest average concentrations of this pro-inflammatory cytokine before treatment (p=0.028) and they also more frequently presented with more active disease (p=0.048). These results imply that the IL6 rs1800795 CC homozygosity may play a rather unfavourable role in RA. This article is protected by copyright. All rights reserved.

show abstract

Section: Characteristics Of Ra Patientsmentioning

confidence: 87%

Section: Characteristics Of Ra Patientsmentioning

confidence: 99%

Interleukin 6 gene polymorphism is associated with protein serum level and disease activity in Polish patients with rheumatoid arthritis

Wielińska

Dratwa

Świerkot

et al. 2018

HLA

View full text Add to dashboard Cite

show abstract

“…However, several studies have reported this association in other disease models. Gaber et al 19 . conducted a study regarding the correlation between serum IL6 and −174 G/C promoter polymorphism in rheumatoid arthritis patients.…”

Section: Discussionmentioning

confidence: 99%

“…found that serum IL6 was elevated in postmenopausal osteoporosis. Gaber et al 19 . showed that the G/C promoter polymorphism at −174 of the IL6 gene had an effect on basal IL6 levels, and the C allele of the IL6 −174 G/C gene was associated with reduced gene expression and reduced plasma levels of IL6.…”

Section: Introductionmentioning

confidence: 99%

The association between interleukin 6 −174 G/C gene polymorphism and the risk of osteoporosis: A meta-analysis

Fajar

Azharuddin

2017

Journal of Taibah University Medical Sciences

View full text Add to dashboard Cite

Objectives This study aimed to investigate the association between the IL6 −174 G/C gene polymorphism and the risk of osteoporosis by performing a meta-analysis. Methods Published literature from PubMed and Embase databases was searched for eligible publications. The following information was extracted from each study: Name of first author, year of publication, country of origin, sample size of cases and controls, and size of each allele. The combined odds ratio (ORs) and 95% confidence intervals (95%CIs) for the association between the IL6 −174 G/C gene polymorphism and the risk of osteoporosis were assessed using a random or fixed effects model. A comprehensive meta-analysis (CMA) 2.0 was used to analyse the data. Results Twelve studies (4923 cases/3431 controls) were included in this meta-analysis. The results indicated that IL6 −174 G/C gene polymorphism was associated with an increased (G vs C, OR 95%CI = 1.29 [1.03–1.62], p = 0.029) and decreased risk of osteoporosis (C vs G, OR 95%CI = 0.77 [0.62–0.97], p = 0.029; CC vs GG + GC, OR 95%CI = 0.58 [0.39–0.88], p = 0.010). Conclusion The IL6 −174 G/C gene polymorphism was shown to be positively correlated with osteoporosis risk.

show abstract

“…Information on the pharmacodynamics of sarilumab were collected from abstracts, the package insert, product information provided to the FDA, published research, introductory sections in the published clinical studies, and other reviews. 9,[15][16][17][18][19][20][21][22] Each author took primary responsibility for the extraction and inclusion of information within a specific section of the article and then reviewed all other sections to ensure accuracy and completeness.…”

Section: Methodsmentioning

confidence: 99%

Sarilumab: Review of a Second IL-6 Receptor Antagonist Indicated for the Treatment of Rheumatoid Arthritis

et al. 2018

View full text Add to dashboard Cite

show abstract

Clinical significance of serum interleukin-6 and −174 G/C promoter polymorphism in Rheumatoid arthritis patients

Cited by 41 publications

References 30 publications

Interleukin 6 gene polymorphism is associated with protein serum level and disease activity in Polish patients with rheumatoid arthritis

Interleukin 6 gene polymorphism is associated with protein serum level and disease activity in Polish patients with rheumatoid arthritis

The association between interleukin 6 −174 G/C gene polymorphism and the risk of osteoporosis: A meta-analysis

Sarilumab: Review of a Second IL-6 Receptor Antagonist Indicated for the Treatment of Rheumatoid Arthritis

Contact Info

Product

Resources

About